The role of pyroptosis and its crosstalk with immune therapy in breast cancer
Pyroptosis is a brand-new category of programmed cell death (PCD) that is brought on by multitudinous inflammasomes, which can recognize several stimuli to pilot the cleavage of and activate inflammatory cytokines like IL-18 and IL-1β is believed to have dual effects on the development of multiple cancers including breast cancer. However, pyroptosis has different effects on cancers depending on the type of tissues and their distinct heredity. Recently, the association between pyroptosis and breast cancer has received more and more attention, and it is thought that inducing pyroptosis could be used as a cancer treatment option. In addition, a great deal of evidence accumulating over the past decades has evinced the crosstalk between pyroptosis and tumor immunological therapy. Thus, a comprehensive summary combining the function of pyroptosis in breast cancer and antitumor immunity is imperative. We portray the prevalent knowledge of the multidimensional roles of pyroptosis in cancer and summarize the pyroptosis in breast cancer principally. Moreover, we elucidate the influence of inflammasomes and pyroptosis-produced cytokines on the tumor microenvironment (TME) of breast cancer. Taken together, we aim to provide a clue to harness pyroptosis rationally and apply it to augment immunotherapy efficiency for breast cancer..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Frontiers in Immunology - 13(2022) |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ling Wu [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Breast cancer |
|---|
| doi: |
10.3389/fimmu.2022.973935 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ031375111 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ031375111 | ||
| 003 | DE-627 | ||
| 005 | 20230307160519.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fimmu.2022.973935 |2 doi | |
| 035 | |a (DE-627)DOAJ031375111 | ||
| 035 | |a (DE-599)DOAJ36827947e83845689da2c7fd291bebed | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC581-607 | |
| 100 | 0 | |a Ling Wu |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The role of pyroptosis and its crosstalk with immune therapy in breast cancer |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Pyroptosis is a brand-new category of programmed cell death (PCD) that is brought on by multitudinous inflammasomes, which can recognize several stimuli to pilot the cleavage of and activate inflammatory cytokines like IL-18 and IL-1β is believed to have dual effects on the development of multiple cancers including breast cancer. However, pyroptosis has different effects on cancers depending on the type of tissues and their distinct heredity. Recently, the association between pyroptosis and breast cancer has received more and more attention, and it is thought that inducing pyroptosis could be used as a cancer treatment option. In addition, a great deal of evidence accumulating over the past decades has evinced the crosstalk between pyroptosis and tumor immunological therapy. Thus, a comprehensive summary combining the function of pyroptosis in breast cancer and antitumor immunity is imperative. We portray the prevalent knowledge of the multidimensional roles of pyroptosis in cancer and summarize the pyroptosis in breast cancer principally. Moreover, we elucidate the influence of inflammasomes and pyroptosis-produced cytokines on the tumor microenvironment (TME) of breast cancer. Taken together, we aim to provide a clue to harness pyroptosis rationally and apply it to augment immunotherapy efficiency for breast cancer. | ||
| 650 | 4 | |a breast cancer | |
| 650 | 4 | |a pyroptosis | |
| 650 | 4 | |a gasdermin | |
| 650 | 4 | |a inflammasomes | |
| 650 | 4 | |a immunotherapy | |
| 653 | 0 | |a Immunologic diseases. Allergy | |
| 700 | 0 | |a Ling Wu |e verfasserin |4 aut | |
| 700 | 0 | |a Hongsheng Lu |e verfasserin |4 aut | |
| 700 | 0 | |a Yin Pan |e verfasserin |4 aut | |
| 700 | 0 | |a Chen Liu |e verfasserin |4 aut | |
| 700 | 0 | |a Jinyan Wang |e verfasserin |4 aut | |
| 700 | 0 | |a Baofu Chen |e verfasserin |4 aut | |
| 700 | 0 | |a Yichao Wang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Frontiers in Immunology |d Frontiers Media S.A., 2011 |g 13(2022) |w (DE-627)DOAJ000031690 |x 16643224 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2022 |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fimmu.2022.973935 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/36827947e83845689da2c7fd291bebed |z kostenfrei |
| 856 | 4 | 0 | |u https://www.frontiersin.org/articles/10.3389/fimmu.2022.973935/full |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1664-3224 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2022 | ||